| Identification | Back Directory | [Name]
1-Propanesulfonamide, N-[2,4,5-trifluoro-3-[[3-(4-morpholinyl)-6-quinoxalinyl]carbonyl]phenyl]- | [CAS]
1425485-87-5 | [Synonyms]
RX208
B-Raf IN 10
RX208 B-Raf IN 10
1-Propanesulfonamide, N-[2,4,5-trifluoro-3-[[3-(4-morpholinyl)-6-quinoxalinyl]carbonyl]phenyl]- | [Molecular Formula]
C22H21F3N4O4S | [MOL File]
1425485-87-5.mol | [Molecular Weight]
494.49 |
| Chemical Properties | Back Directory | [Boiling point ]
688.2±65.0 °C(Predicted) | [density ]
1.464±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
5.03±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. Uplarafenib shows antitumor activity[1]. | [IC 50]
BRAF-V600E: < 50 nM (IC50); Braf: 50-100 nM (IC50) | [References]
[1] Yong-Liang Zhu, et al. Certain Chemical Entities, Compositions, and Methods. Patent US20130053384 A1. |
|
| Company Name: |
Pharmalego
|
| Tel: |
021-02158596539 18321033991 |
| Website: |
cn.pharmalego.com/ |
|